Vaccination with a chaperone complex based on PSCA and GRP170 adjuvant enhances the CTL response and inhibits the tumor growth in mice (Q39679340)

13 September 2017

title

Vaccination with a chaperone complex based on PSCA and GRP170 adjuvant enhances the CTL response and inhibits the tumor growth in mice (English)

1 reference

13 September 2017

0 references

Wenqian Huo

1

1 reference

13 September 2017

Jin Ye

2

1 reference

13 September 2017

Rongrong Liu

3

1 reference

13 September 2017

Jin Chen

4

1 reference

13 September 2017

Qiansheng Li

5

1 reference

13 September 2017

language of work or name

English

0 references

publication date

14 July 2010

1 reference

13 September 2017

number of pages

5

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

13 September 2017

volume

28

1 reference

13 September 2017

issue

38

1 reference

13 September 2017

page(s)

6333-6337

1 reference

Molecular and cellular biology of prostate cancer

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.093

Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.093

Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.093

The 170-kDa glucose-regulated stress protein is an endoplasmic reticulum protein that binds immunoglobulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.093

The 170 kDa glucose regulated stress protein is a large HSP70-, HSP110-like protein of the endoplasmic reticulum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.093

A novel subfamily of Hsp70s in the endoplasmic reticulum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.093

The hsp110 and Grp1 70 stress proteins: newly recognized relatives of the Hsp70s

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.093

Multiple molecular chaperones complex with misfolded large oligomeric glycoproteins in the endoplasmic reticulum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.093

A microsomal ATP-binding protein involved in efficient protein transport into the mammalian endoplasmic reticulum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.093

A novel Hsp70 of the yeast ER lumen is required for the efficient translocation of a number of protein precursors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.093

Identification of novel peptide binding proteins in the endoplasmic reticulum: ERp72, calnexin, and grp170.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.093

LHS1 and SIL1 provide a lumenal function that is essential for protein translocation into the endoplasmic reticulum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.093

Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccine activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.093

Hsp110 protects heat-denatured proteins and confers cellular thermoresistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.093

7 January 2021

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.093

Hormone refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.093

Prospects of immunotherapy for the treatment of prostate carcinoma--a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.093

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.093

Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.093

A recombinant vaccinia virus expressing human prostate‐specific antigen (PSA): Safety and immunogenicity in a non‐human primate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.093

Target antigens for prostate cancer immunotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.093

Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.093

A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.093

Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.093

Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.093

Heat shock protein-peptide complexes in cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.093

Heat shock proteins transfer peptides during antigen processing and CTL priming

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.093

Heat shock protein-based cancer vaccines and related thoughts on immunogenicity of human tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.093

Heat shock, stress proteins, chaperones, and proteotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.093

Tumor rejection antigens of chemically induced sarcomas of inbred mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.093

Heat shock proteins in immune response to cancer: the Fourth Paradigm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.093

Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.093

The chaperoning properties of mouse grp170, a member of the third family of hsp70 related proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.093

Immunization with tumor-derived ER chaperone grp170 elicits tumor-specific CD8+ T-cell responses and reduces pulmonary metastatic disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.093

Heat shock protein vaccines against cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.093

10.1016/J.VACCINE.2010.06.093

7 January 2021

Identifiers

DOI

1 reference

13 September 2017

1 reference